In the pharmaceutical sector, API sourcing strategy is essential — especially when only one manufacturer is currently approved.

Deltapharma proposes Nimesulide API from Mangalam (India), supported by CEP, offering regulatory compliance, reliable manufacturing standards and the opportunity to homologate a qualified second source.

Introducing a CEP-backed alternative manufacturer can help reduce supply chain risks, improve procurement flexibility and strengthen long-term business continuity for pain management products.

This approach reflects Deltapharma’s commitment to selecting reliable active ingredients supported by regulatory expertise and trusted global partnerships.

As part of the Faravelli Group, Deltapharma combines pharmaceutical market knowledge with a consolidated presence across Europe.

Contact Deltapharma to receive regulatory documentation and commercial details.